Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Plasma Fractionation Market Outlook

The global plasma fractionation market value was USD 27.96 billion in 2023, driven by the growing demand for plasma-derived therapies across the globe. The market size is anticipated to grow at a CAGR of 6.7% during the forecast period of 2024-2032 to achieve a value of USD 50.11 billion by 2032.

Key Trends in the Market

Plasma fractionation is the process of breaking down and separating the different components of blood plasma collected from donors. The proteins separated from the plasma are used as a therapeutic product for prevention and treatment of life-threatening diseases such as immunological disorders, blood clotting disorders, and others.

  • Respiratory diseases along with AATD (Alpha-1-antitrypsin deficiency) are increasing and becoming widely prevalent. More people are undergoing therapy for treatment of such disease which is contributing to the growth of the market globally. AATD is an unrecognised chronic metabolic genetic disorder which can also cause emphysema.
  • Bleeding disorders such as haemophilia have been rising which are characterised by impaired blood coagulation. One of the main applications of plasma fractionation is the treatment of haemophilia which is helping in the growth of the plasma fractionation market.
  • Plasma collection centres are spread all over the world in large numbers so that human plasma that can be used for treatment of more individuals without facing shortages. Post-collection, there is need for plasma fractionation, making it a key trend for the market.

plasma fractionation market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

Based on product, the plasma fractionation market can be segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and others. On the basis of application, it can be divided into neurology, immunology, haematology, rheumatology, and others. Based on processing technology it is divided into ion exchange chromatography, affinity chromatography, cryopreservation, ultrafiltration, and microfiltration. By end use the market is divided into hospitals and clinics, clinical research laboratories, academic institutes, and others. On a regional basis, the market can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East, and Africa.

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global plasma fractionation market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.  

  • CSL Plasma LLC
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Biotest Group
  • Baxter International Inc.
  • Others

plasma fractionation market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Share by Product Type

Immunoglobulins hold a significant share in the market for plasma fractionation because of their ability to treat autoimmune diseases and increase immune response. Coagulation factor concentrates help in the formation of blood clots whereas albumin is involved in the movement of molecules through blood. HIV progression is slowed down with the help of protease inhibitors. All these products largely contribute to the growth of the market.\

Market Share by End Use

Improved infrastructure and facilities in hospitals have made it the largest shareholder in the market for plasma fractionation. Hospitals and clinics are now providing treatment facilities for various autoimmune diseases using plasma products which is why it is predicted to dominate the market in the forecast period as well. Clinical research laboratories are also researching for new and innovative therapy techniques, contributing to the growth of the plasma fractionation market.

plasma fractionation market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape 

CSL Plasma LLC was founded in 1916 and has its headquarter in Florida, United States. Its parent company CSL Behring makes use of human plasma to treat bleeding disorders, neurological disorders, immune deficiency, inherited respiratory disease, and hereditary angioedema.

Grifols S.A. was founded in 1940. Based out of Barcelona, Spain, it is a Spanish company specialising in the manufacture of pharmaceuticals and chemicals. It mainly produces blood plasma-based products among other instruments, and reagents to be used in clinical testing.

Biotest Group is known globally for developing and supplying biotherapeutic drugs and plasma protein products. It was established in 1946 and has its headquarter in Dreieich, Germany.

Other market players include Takeda Pharmaceutical Company Limited, and Baxter International Inc., among others.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment

  • Product
  • Method
  • Application
  • End User
  • Region
Breakup by Product
  • Immunoglobulins
  • Coagulation Factor Concentrates
  • Albumin
  • Protease Inhibitor
  • Others
Breakup by Method
  • Centrifugation
  • Depth Filtration
  • Chromatography
  • Others
Breakup by Application
  • Neurology
  • Hematology
  • Oncology
  • Immunology
  • Pulmonology
  • Others
Breakup by End User
  • Hospitals and Clinics
  • Clinical Research Laboratories
  • Academic Institutes
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • CSL Plasma LLC
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Biotest Group
  • Baxter International Inc.
  • OCTAPHARMA AG
  • KEDRION S.P.A
  • LFB S.A.
  • BIOTEST AG
  • SANQUIN
  • BIO PRODUCTS LABORATORY LTD.
  • INTAS PHARMACEUTICALS LTD.
  • GC Pharma
  • Emergent Biosolutions
  • Japan Blood Products Organisation

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The plasma fractionation market was valued at USD 27.96 billion in 2023.

The market is expected to grow at a CAGR of 6.7% from 2024 to 2032 to reach USD a value of USD 50.11 billion by 2032.

The major market drivers are increasing geriatric population and increasing use of immunoglobulins.

Major trends in the market are prevalence of respiratory diseases and bleeding disorders and increase in the number of plasma collection centres worldwide.

The regional markets can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.

Key players in the global plasma fractionation market are CSL Plasma LLC, Grifols, S.A., Takeda Pharmaceutical Company Limited, Biotest Group, and Baxter International Inc., among others.

Plasma fractionation is the process of breaking down and separating the different components of blood plasma collected from donors.

The market is segmented based on product, application, processing technology, end use, and region.

Proteins separated from plasma are used as a therapeutic product for prevention and treatment of life-threatening diseases such as immunological disorders, blood clotting disorders, and others.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124